J&J receives three subpoenas regarding subsidiary oversight
Pharma Compliance Alert, March 14, 2007
Johnson & Johnson (J&J) has received three separate subpoenas from three U.S. Attorney's offices. According to J&J, the subpoenas are from the U.S. Attorney's Offices in Philadelphia, Boston, and San Francisco and relate to investigations that the company had previously disclosed in Securities and Exchange Commission filings.
The subpoenas seek information regarding the sales and marketing of schizophrenia treatment Risperdal by Janssen, migraine treatment Topamax by Ortho-McNeil, and heart failure drug Natracor by Scios, all J&J subsidiaries. According to J&J, the subpoenas request information about its corporate supervision and oversight of these three subsidiaries, including its sales and marketing techniques.
J&J's subsidiaries have been the focus of attention in recent weeks. In February, J&J's Centocor unit received a subpoena in connection with an investigation into the average selling price (ASP) calculations for the drug Remicade. The company also notified the Department of Justice and the Securities and Exchange Commission last month that certain foreign subsidiaries may have made improper payments to sell medical devices.
Go to the J&J Web site to read its statement about the subpoenas.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q&A tackles coding questions about injections and infusions
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- Case Management Monthly, June 2012
- Searched